DEPTOR polymorphisms influence late complications in Type 2 diabetes patients.

Abstract:

:Aim: We investigated if DEPTOR polymorphisms influence metabolic parameters and risk for vascular complications in Type 2 diabetes (T2D) patients. Methods: T2D patients were genotyped for DEPTOR rs7840156, rs2271900 and rs4871827. We built low homology model of DEPTOR to check the position of two investigated substitutions within the protein 3D structure. Results: Carriers of polymorphic DEPTOR rs4871827 A allele had higher HDL cholesterol than noncarriers (p = 0.008). Risk for macrovascular and microvascular complications was increased in rs4871827 GG normal genotype carriers (p = 0.006 and p = 0.021, respectively). Low homology model of DEPTOR has shown that p.Ser389Asn substitution resulting from rs4871827 polymorphism is located at the interaction surface with mTOR. Conclusion: Our data suggest role of DEPTOR polymorphism in T2D vascular complication. First draft submitted: xxx; Accepted for publication: xxx; Published online: TBC.

journal_name

Pharmacogenomics

journal_title

Pharmacogenomics

authors

Klen J,Goričar K,Horvat S,Stojan J,Dolžan V

doi

10.2217/pgs-2019-0058

subject

Has Abstract

pub_date

2019-08-01 00:00:00

pages

879-890

issue

12

eissn

1462-2416

issn

1744-8042

journal_volume

20

pub_type

杂志文章
  • A review of consent practices and perspectives for pharmacogenetic testing.

    abstract:AIM:We aimed to understand consent practices for pharmacogenetic (PGx) testing. METHODS:We conducted a literature review and analysis of consent forms from clinical laboratories offering PGx testing. RESULTS:Our review of the literature shows a lack of consensus about the need for and type of informed consent for PGx...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2016-0039

    authors: Haga SB,Mills R

    更新日期:2016-09-01 00:00:00

  • Genetic factors that confer sensitivity to HAART in HIV-infected subjects: implication of a benefit of an earlier initiation of HAART.

    abstract::EVALUATION OF: Ahuja SK, Kulkarni H, Catano G et al.: CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat. Med. 14(4), 413-420 (2008). It is widely accepted that the effect of highly active antiretroviral therapy (HAART) varies widely among HIV...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.9.1347

    authors: Nakajima T,Kimura A

    更新日期:2008-09-01 00:00:00

  • Parkinson's disease pharmacogenomics: new findings and perspectives.

    abstract::Parkinson's disease (PD) is unique among neurodegenerative disorders because a highly effective pharmacological symptomatic treatment is available. The marked variability in drug response and in adverse profiles associated with this treatment led to the search of genetic markers associated with these features. We pres...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.93

    authors: Schumacher-Schuh AF,Rieder CR,Hutz MH

    更新日期:2014-06-01 00:00:00

  • Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy.

    abstract:UNLABELLED:Glutathione S-transferases (GSTs) participate in the detoxification of chemotherapeutic agents. Genetic polymorphisms in GST genes (GSTP1 Ile105Val, copy-number variants of GSTM1 and GSTT1) that lead to diminished enzyme activity have been associated with increased chemotherapeutic treatment benefit in color...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.09.132

    authors: Funke S,Timofeeva M,Risch A,Hoffmeister M,Stegmaier C,Seiler CM,Brenner H,Chang-Claude J

    更新日期:2010-01-01 00:00:00

  • Genetics of antipsychotic-induced weight gain: update and current perspectives.

    abstract::Antipsychotic medications are used to effectively treat various symptoms for different psychiatric conditions. Unfortunately, antipsychotic-induced weight gain (AIWG) is a common side effect that frequently results in obesity and secondary medical conditions. Twin and sibling studies have indicated that genetic factor...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,meta分析

    doi:10.2217/pgs.13.207

    authors: Kao AC,Müller DJ

    更新日期:2013-12-01 00:00:00

  • ALK gene alterations in cancer: biological aspects and therapeutic implications.

    abstract::ALK was first reported in 1994 as a translocation in anaplastic large cell lymphoma and then described with different abnormalities in a number of tumors. Recently, a shortly accumulated biomedical research clarified the numerous biological processes underlying its ability to support cancer development, growth and pro...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2016-0166

    authors: Palmirotta R,Quaresmini D,Lovero D,Silvestris F

    更新日期:2017-02-01 00:00:00

  • Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.

    abstract::PON1 is a key component of high-density lipoproteins (HDLs) and is at least partially responsible for HDL's antioxidant/atheroprotective properties. PON1 is also associated with numerous human diseases, including cardiovascular disease, Parkinson's disease and cancer. In addition, PON1 metabolizes a broad variety of s...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.13.147

    authors: Kim DS,Marsillach J,Furlong CE,Jarvik GP

    更新日期:2013-09-01 00:00:00

  • Requirements for comprehensive pharmacogenetic genotyping platforms.

    abstract::Recent research highlighted the large extent of rare variants in pharmacogenes and, on this basis, it was estimated that rare variants account for 30-40% of the functional variability in pharmacogenes. It has been proposed that comprehensive next-generation sequencing (NGS)-based sequencing of pharmacogenes could soon...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2016-0023

    authors: Lauschke VM,Ingelman-Sundberg M

    更新日期:2016-06-01 00:00:00

  • Eradication of T315I mutation in chronic myeloid leukemia without third-generation tyrosine kinase inhibitor: a case report.

    abstract::We report the case of a patient bearing a T315I-mutant chronic myeloid leukemia resistant to nilotinib, successfully treated with omacetaxine and then with dasatinib. After 9 months of nilotinib, the patient achieved a major molecular response but relapsed 3 months later due to the T315I mutation. Because third-genera...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.25

    authors: Venton G,Colle J,Mercier C,Fanciullino R,Ciccolini J,Ivanov V,Suchon P,Sebahoun G,Beaufils N,Gabert J,Hadjaj D,Costello R

    更新日期:2015-01-01 00:00:00

  • Genomics-based drug design targets the AT-rich malaria parasite: implications for antiparasite chemotherapy.

    abstract::Evaluation of: Woynarowski JM, Krugliak M, Ginsburg H: Pharmacogenomic analyses of targeting the AT-rich malaria parasite genome with AT-specific alkylating drugs. Mol. Biochem. Parasitol. 154(1), 70-81 (2007) [1] . The sequencing of the malaria genome sought to expose the parasite's ability to cause disease and ident...

    journal_title:Pharmacogenomics

    pub_type: 评论,杂志文章

    doi:10.2217/14622416.8.9.1267

    authors: Yanow SK,Purcell LA,Lee M,Spithill TW

    更新日期:2007-09-01 00:00:00

  • Genetic susceptibility to schizophrenia: role of dopaminergic pathway gene polymorphisms.

    abstract:AIM:We investigated 16 polymorphisms from three genes, dopamine receptor D2 (DRD2), catechol-O-methyl transferase (COMT) and brain derived neurotrophic factor (BDNF), which are involved in the dopaminergic pathways, and have been reported to be associated with susceptibility to schizophrenia and response to antipsychot...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.10.2.277

    authors: Gupta M,Chauhan C,Bhatnagar P,Gupta S,Grover S,Singh PK,Purushottam M,Mukherjee O,Jain S,Brahmachari SK,Kukreti R

    更新日期:2009-02-01 00:00:00

  • EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions.

    abstract::Type B adverse drug reactions (ADRs) are often serious, limit the usefulness of drugs that are otherwise effective, and increase the risks of drug development as they often lead to postmarketing withdrawal. There is evidence that susceptibility to at least some Type B ADRs is under strong genetic influence. Identifyin...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.7.4.633

    authors: Molokhia M,McKeigue P

    更新日期:2006-06-01 00:00:00

  • Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU.

    abstract:AIM:To determine if copy number variants contribute to warfarin dose requirements, we investigated CYP2C9, VKORC1, CYP4F2, GGCX and CALU for deletions and duplications in a multiethnic patient population treated with therapeutic doses of warfarin. PATIENTS & METHODS:DNA samples from 178 patients were subjected to copy...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.11.156

    authors: Scott SA,Patel M,Martis S,Lubitz SA,van der Zee S,Yoo C,Edelmann L,Halperin JL,Desnick RJ

    更新日期:2012-02-01 00:00:00

  • Pharmacogenomics of beta2-agonist: key focus on signaling pathways.

    abstract::Asthma is one of the most common respiratory diseases, where inhalation and exhalation are obstructed due to narrowing of the airways by broncho-constriction or by inflammation. Among all the available anti-asthma therapies, beta2-agonists are the most effective bronchodilators available, and give rapid relief of asth...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.7.6.919

    authors: Bhatnagar P,Guleria R,Kukreti R

    更新日期:2006-09-01 00:00:00

  • Drug-induced liver injury: insights from genetic studies.

    abstract::Drug-induced liver injury (DILI) is an increasing health problem and a challenge for physicians, regulatory bodies and the pharmaceutical industry, not only because of its potential severity and elusive pathogenesis but also because it is often inaccurately diagnosed, commonly missed entirely and more often not report...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.09.111

    authors: Andrade RJ,Robles M,Ulzurrun E,Lucena MI

    更新日期:2009-09-01 00:00:00

  • VMAT2 gene (SLC18A2) variants associated with a greater risk for developing opioid dependence.

    abstract::Aim: To determine if selected serotonergic and noradrenergic gene variants are associated with heroin addiction. Subjects & methods: A total of 126 variants in 19 genes in subjects with Dutch European ancestry from The Netherlands. Subjects included 281 opioid-dependent volunteers in methadone maintenance or heroin-as...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2018-0137

    authors: Randesi M,van den Brink W,Levran O,Blanken P,van Ree JM,Ott J,Kreek MJ

    更新日期:2019-04-01 00:00:00

  • Cambridge Healthtech Institute's Third Annual Conference on Lab-on-a-Chip and Microarrays. 22-24 January 2001, Zurich, Switzerland.

    abstract::Cambridge Healthtech Institute's Third Annual Conference on Lab-on-a-Chip and Microarray technology covered the latest advances in this technology and applications in life sciences. Highlights of the meetings are reported briefly with emphasis on applications in genomics, drug discovery and molecular diagnostics. Ther...

    journal_title:Pharmacogenomics

    pub_type:

    doi:10.1517/14622416.2.1.73

    authors: Jain KK

    更新日期:2001-02-01 00:00:00

  • Epilepsy pharmacogenetics.

    abstract::Large interindividual variation in efficacy and adverse effects of anti-epileptic therapy presents opportunities and challenges in pharmacogenomics. Although the first true association of genetic polymorphism in drug-metabolizing enzymes with anti-epileptic drug dose was reported 10 years ago, most of the findings hav...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.09.34

    authors: Kasperaviciūte D,Sisodiya SM

    更新日期:2009-05-01 00:00:00

  • Influence of the CYP2C9*3 allele on the pharmacological interaction between warfarin and simvastatin.

    abstract::A letter in response to: Andersson ML, Eliasson E, Lindh JD. A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. Pharmacogenomics 13(7), 757-762 (2012). ...

    journal_title:Pharmacogenomics

    pub_type: 评论,信件

    doi:10.2217/pgs.12.151

    authors: Botton MR,Hutz MH,Suarez-Kurtz G

    更新日期:2012-11-01 00:00:00

  • Genetics of chronic obstructive pulmonary disease: a succinct review, future avenues and prospective clinical applications.

    abstract::Chronic obstructive pulmonary disease (COPD) is influenced by genetic and environmental factors. A large number of candidate gene-association studies and genome-wide linkage scans have been conducted to elucidate the genetic architecture underlying this disease. The compilation of these studies clearly revealed the co...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.09.10

    authors: Bossé Y

    更新日期:2009-04-01 00:00:00

  • Effect of genetic polymorphisms in SREBF-SCAP pathway on therapeutic response to rosuvastatin in Saudi metabolic syndrome patients.

    abstract:AIM:Genetic variants contribute to statins' therapeutic variability. SREBF-SCAP pathway is a key player in lipid homeostasis. Hence, effect of SREBF-SCAP polymorphisms on therapeutic response was studied. PATIENTS & METHODS:Metabolic syndrome patients of either sex were prescribed rosuvastatin 10 mg for 24 weeks. Clin...

    journal_title:Pharmacogenomics

    pub_type: 临床试验,杂志文章

    doi:10.2217/pgs-2017-0181

    authors: Rafeeq MM,Habib HS,Murad HAS,Gari MA,Gazzaz ZJ

    更新日期:2018-02-01 00:00:00

  • Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL.

    abstract:INTRODUCTION:One of the causes of long-term morbidity associated with the treatment of acute lymphoblastic leukemia (ALL) is late neurotoxicity manifesting as impairment of higher cognitive functions. Cranial radiation therapy (CRT) and chemotherapeutic agents, particularly methotrexate (MTX), are often suggested to be...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.1517/14622416.6.3.293

    authors: Krajinovic M,Robaey P,Chiasson S,Lemieux-Blanchard E,Rouillard M,Primeau M,Bournissen FG,Moghrabi A

    更新日期:2005-04-01 00:00:00

  • Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.

    abstract:AIMS:The importance of polymorphisms in the dihydropyrimidine dehydrogenase gene (DPYD) for the prediction of severe toxicity in 5-fluorouracil (5-FU)-based chemotherapy is still unclear. This study aims to assess the predictive value of DPYD variation with respect to previously described DPYD variants for 5-FU toxicit...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.09.28

    authors: Amstutz U,Farese S,Aebi S,Largiadèr CR

    更新日期:2009-06-01 00:00:00

  • Microarray expression technology: from start to finish.

    abstract::The recent introduction of new microarray expression technologies and the further development of established platforms ensure that the researcher is presented with a range of options for performing an experiment. Whilst this has opened up the possibilities for future applications, such as exon-specific arrays, increas...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.7.1.123

    authors: Elvidge G

    更新日期:2006-01-01 00:00:00

  • Pharmacogenetics of aspirin-intolerant asthma.

    abstract::Leukotriene overproduction is the major characteristic of aspirin-intolerant asthma (AIA). Most studies examining the molecular genetic mechanisms of AIA have focused on leukotriene-related genes, including ALOX5, LTC4S, TXA2R and prostanoid-receptor genes. One study suggested that the human leukocyte antigen (HLA) al...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.1.85

    authors: Kim SH,Hur GY,Choi JH,Park HS

    更新日期:2008-01-01 00:00:00

  • CYP3A5*3 and CYP2C8*3 variants influence exposure and clinical outcomes of tacrolimus-based therapy.

    abstract::Aim: The influence of variants in pharmacokinetics-related genes on long-term exposure to tacrolimus (TAC)-based therapy and clinical outcomes was investigated. Patients & methods: Brazilian kidney recipients were treated with TAC combined with everolimus (n = 178) or mycophenolate sodium (n = 97). The variants in CYP...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2019-0120

    authors: Genvigir FDV,Campos-Salazar AB,Felipe CR,Tedesco-Silva H Jr,Medina-Pestana JO,Doi SQ,Cerda A,Hirata MH,Herrero MJ,Aliño SF,Hirata RDC

    更新日期:2020-01-01 00:00:00

  • Stem cell-derived neurons in the development of targeted treatment for schizophrenia and bipolar disorder.

    abstract::The recent advent of induced pluripotent stem cells has enabled the study of patient-specific and disease-related neurons in vitro and has facilitated new directions of inquiry into disease mechanisms. With these approaches, we now have the possibility of correlating ex vivo cellular phenotypes with individual patient...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2016-0187

    authors: Watmuff B,Liu B,Karmacharya R

    更新日期:2017-04-01 00:00:00

  • Evaluation of a shared pharmacogenomics curriculum for pharmacy students.

    abstract:AIM:This national dissemination study evaluated pharmacy students' self-reported overall ability, self-efficacy and attitudes toward applying pharmacogenomics and perceptions of Pharmacogenomics Education Program, a shared pharmacogenomics curriculum. PATIENTS & METHODS:Following a series of train-the-trainer programs...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.181

    authors: Lee KC,Hudmon KS,Ma JD,Kuo GM

    更新日期:2015-01-01 00:00:00

  • Genetic variants associated with warfarin dosage in Kuwaiti population.

    abstract::Assessing the distinct prevalence or absence of genetic variants associated with differential response to the anticoagulant medication of warfarin in different population groups is actively pursued by pharmacogenomics community. Populations from Arabian Peninsula are underrepresented in such studies. By way of examini...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2017-0020

    authors: John SE,Antony D,Eaaswarkhanth M,Hebbar P,Alkayal F,Tuomilehto J,Alsmadi O,Thanaraj TA

    更新日期:2017-06-01 00:00:00

  • BDNF (Val66Met) genetic polymorphism is associated with vulnerability for methamphetamine dependence.

    abstract:AIM:Association of the brain-derived neurotrophic factor (BDNF) genetic polymorphism rs6265 (Val66Met) with methamphetamine (METH) dependence and METH-induced psychosis was investigated in the Thai population. MATERIALS & METHODS:The rs6265 genotype was determined in 100 male METH-dependent subjects and 102 controls u...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.96

    authors: Iamjan SA,Thanoi S,Watiktinkorn P,Nudmamud-Thanoi S,Reynolds GP

    更新日期:2015-01-01 00:00:00